HomeCompareMLLCF vs NOBL

MLLCF vs NOBL: Dividend Comparison 2026

MLLCF yields 40.32% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLLCF wins by $213.1K in total portfolio value
10 years
MLLCF
MLLCF
● Live price
40.32%
Share price
$4.96
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$236.0K
Annual income
$40,141.97
Full MLLCF calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — MLLCF vs NOBL

📍 MLLCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLLCFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLLCF + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLLCF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLLCF
Annual income on $10K today (after 15% tax)
$3,427.42/yr
After 10yr DRIP, annual income (after tax)
$34,120.67/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, MLLCF beats the other by $33,908.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLLCF + NOBL for your $10,000?

MLLCF: 50%NOBL: 50%
100% NOBL50/50100% MLLCF
Portfolio after 10yr
$129.4K
Annual income
$20,195.87/yr
Blended yield
15.60%
📊

Analyst Conviction Gap

Where Wall Street is split right now

MLLCF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
-1.2
Piotroski
1/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLLCF buys
0
NOBL buys
0
No recent congressional trades found for MLLCF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLLCFNOBL
Forward yield40.32%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$236.0K$22.9K
Annual income after 10y$40,141.97$249.78
Total dividends collected$178.0K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: MLLCF vs NOBL ($10,000, DRIP)

YearMLLCF PortfolioMLLCF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$14,732$4,032.26$10,917$217.08+$3.8KMLLCF
2$21,315$5,551.80$11,903$221.48+$9.4KMLLCF
3$30,314$7,507.11$12,962$225.68+$17.4KMLLCF
4$42,415$9,978.09$14,099$229.68+$28.3KMLLCF
5$58,431$13,047.54$15,319$233.49+$43.1KMLLCF
6$79,320$16,798.63$16,628$237.10+$62.7KMLLCF
7$106,185$21,312.20$18,033$240.53+$88.2KMLLCF
8$140,281$26,663.87$19,539$243.78+$120.7KMLLCF
9$183,022$32,921.38$21,154$246.86+$161.9KMLLCF
10$235,976$40,141.97$22,884$249.78+$213.1KMLLCF

MLLCF vs NOBL: Complete Analysis 2026

MLLCFStock

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Full MLLCF Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this MLLCF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLLCF vs SCHDMLLCF vs JEPIMLLCF vs OMLLCF vs KOMLLCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.